IMNM — Immunome Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Immunome Inc

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjug… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$20.88
Market Cap$2.49B
Float94.4M
Shares Outstanding113.3M
Price/Sales (TTM)621.11
vs. Analyst Target+70.2% to analyst PT
Operating Margin (TTM)-5698.83%
Revenue (TTM)$4.0M
Dividend RateNone
Analyst Target Price$35.54 (9 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$17.1M -$755,000 -$11.5M
2021 N/A -$24.7M -$755,000 -$24.4M
2022 $6.6M -$36.9M -$631,000 -$36.3M
2023 $14.0M -$107M $14.0M -$28.0M
2024 $9.0M -$293M $9.0M -$151M
2025 $6.9M -$212M $4.0M -$211M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $4.0M -$43.4M
Sep 2025 N/A -$57.5M
Dec 2025 N/A -$69.9M
Mar 2026 N/A -$53.8M

Ownership & Float

Insider Ownership7.3%
Institutional Ownership104.0%
Short Float19.8%
% of All Funds Holding2.23%
Number of Funds Holding183

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$21.77Near-term / short-term trend
Weekly40-Week SMA$18.51Medium-term trend
Weekly80-Week SMA$14.08Cyclical trend (business cycle)
Weekly200-Week SMA$11.44Secular trend (multi-year)
Monthly10-Month SMA$18.94Near-term monthly trend
Monthly20-Month SMA$14.48Medium-term monthly trend
Monthly40-Month SMA$12.94Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$11.50 support 1.27x 6 months ago
$9.60 support 1.74x 7 months ago
$6.70 support 1.38x 12 months ago
$24.80 resistance 2.48x 24 months ago

Historical Earnings Reactions (23 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.23% -0.08% 43.48% 7.05% -2.67%
1 Day 1.16% 0.16% 52.17% 23.03% -10.41%
1 Week 0.77% -3.45% 39.13% 45.65% -25.15%
2 Weeks 1.52% -1.23% 45.45% 41.30% -28.09%
1 Month 5.18% 0.84% 50.00% 72.16% -40.48%

Next earnings: May 11, 2026

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.00% 44.9% 263
Tuesday -0.01% 45.4% 291
Wednesday 0.28% 49.1% 289
Thursday 0.63% 48.0% 281
Friday 0.20% 47.5% 282

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 104.0%

Insider Transactions — Smart Summary

Total insider ownership: 7.3%

12-Month Insider Activity Summary

Total Filings11
Net Value+$412,458.427
Net Shares Change-550,109
% of Float-0.6%
C-Suite Filings7
Clusters Detected2

Key Insiders

NameTitleNet ValueFilingsActivity
SIEGALL CLAY B President and CEO +$1.7M 4 4 buy
Rosett Max Chief Financial Officer -$1.3M 1 N/A
WAGENHEIM PHILIP -$1.3M 1 1 sell
Tsai Philip Chief Technical Officer +$204,900 1 1 buy
Higgins Jack Chief Scientific Officer -$204,238.32 1 N/A
BIENAIME JEAN JACQUES +$90,570 2 2 buy

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-12-18 – 2025-12-30 5 3 -$6.9M 4 C-suite
2026-03-31 – 2026-04-03 3 3 -$1.0M 3 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-03-31 SIEGALL CLAY B President and CEO +$500,601.5 Transaction at $19.67, now +6.2%
2026-03-12 BIENAIME JEAN JACQUES +$43,670 Transaction at $21.84, now -4.4%
2025-12-22 Tsai Philip Chief Technical Officer +$204,900 Transaction at $20.49, now +1.9%
2025-12-22 SIEGALL CLAY B President and CEO +$149,053.44 Transaction at $20.48, now +2.0%
2025-12-18 SIEGALL CLAY B President and CEO +$999,986.5 Transaction at $21.50, now -2.9%
2026-03-23 WAGENHEIM PHILIP -$1.3M Transaction at $20.55, now +1.6%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Immunome Inc (IMNM) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for IMNM on Trend Edge →